Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06784752 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
A Phase 3 study of Somatostatin Receptor Positive (SSTR+) and Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
- 20
- Study locations
NCT06784752 is a Phase 3 study of Somatostatin Receptor Positive (SSTR+) and Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 240 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT06784752, a Phase 3 study of Somatostatin Receptor Positive (SSTR+) and Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
Conditions Studied
Interventions
- RADIATION [177Lu]Lu-DOTA-TATE
- DRUG Octreotide LAR
Study Locations (20)
Virginia
- Virginia Cancer Specialists - Fairfax
- Virginia Oncology Associates - Norfolk
- Blue Ridge Cancer Center - Wytheville
Connecticut
- Hartford Hospital - Hartford
- Yale New Haven Hospital - New Haven
Texas
- TxO Austin Midtown - Austin
- Texas Oncology - Dallas
Ontario
- Novartis Investigative Site - London
- Novartis Investigative Site - Toronto
Arizona
- Mayo Clinic Arizona - Scottsdale
Arkansas
- Highlands Oncology Group - Fayetteville
Colorado
- Rocky Mountain Cancer Centers - Denver
Florida
- Mayo Clinic Jacksonville - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2025-05-30 |
| Est. Completion | 2034-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06784752
The ClinicalTrials.gov registry entry for NCT06784752 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Somatostatin Receptor Positive (SSTR+) appearing as the primary indexed condition, and to 2 interventions - of which [177Lu]Lu-DOTA-TATE is the first listed.
NCT06784752 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Virginia, Connecticut, Texas.
Frequently Asked Questions
What is clinical trial NCT06784752 about?
NCT06784752 is a clinical study titled "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET". The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<...
What is the current status of trial NCT06784752?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2025-05-30. Estimated completion is 2034-01-05.
What conditions does trial NCT06784752 study?
This clinical trial studies the following conditions: Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET).
What interventions are being tested in trial NCT06784752?
The interventions under investigation include: [177Lu]Lu-DOTA-TATE (RADIATION), Octreotide LAR (DRUG).
Who is sponsoring clinical trial NCT06784752?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06784752 being conducted?
This trial has 20 study locations across Arizona, Arkansas, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Somatostatin Receptor Positive (SSTR+)
All registered trials for this condition
Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.